The Drugs Controller General of India’s restricted emergency approval to Bharat Biotech’s Covaxin has raised questions over the transparency of the process of granting approvals. Covaxin was granted restricted emergency approval by the DCGI on Sunday, along with the Serum Institute of India’s Covishield. While the panel is believed to have considered the phase 3 data of Covishield’s UK trials, no such data of phase 3 trials is available for Covaxin. For more, watch the full video.